Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Impact · against what's priced in

Vanda Pharmaceuticals' BLA submission for imsidolimab is a material positive catalyst that advances the drug toward commercialization with strong Phase 3 efficacy data. AnaptysBio also benefits as the licensor of the asset, though the impact is secondary to the primary developer.

VNDA+0.70: No priced-in read yet

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

What matters in this story

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

What matters in this story

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

How each ticker is affected

Connected tickers

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

What matters in this story

Next reads from the same story arc

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

What matters in this story

Next reads from the same story arc

Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout

How each ticker is affected

Connected tickers

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label